AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21346159 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose remifentanil (0.4 μg · kg(‐1) · min(‐1))
Number of subjects: 60
Study 18432177 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) with antiproliferative drugs attached via polymers
Number of subjects: 0
Study 18432177 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 0
Study 17065539 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training using force platform biofeedback (15 sessions)
Number of subjects: 41
Study 17065539 — intervention group
Group type: COMPARATOR
Intervention: Conventional stroke inpatient rehabilitation programme
Number of subjects: 41
Study 12763708 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical trigger exposure
Number of subjects: 36
Study 12763708 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 36
Study 14596755 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (no active intervention)
Number of subjects: 755
Study 14596755 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 755
Study 11206016 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive approach
Number of subjects: 8000
Study 11206016 — intervention group
Group type: COMPARATOR
Intervention: Conservative approach
Number of subjects: 8000
Study 11206016 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (VANQWISH trial)
Number of subjects: 8000
Study 11206016 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine invasive approach (OASIS registry)
Number of subjects: 8000
Study 11206016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-guided strategy (GUSTO-IIB and PURSUIT trials)
Number of subjects: 8000
Study 11206016 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned revascularization (FRISC II trial)
Number of subjects: 8000
Study 8666176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography (TED) with incremental dobutamine infusion: 5 to 40 ncg/kg/min, continued with atropine 0.25 to 1 mg iv if necessary
Number of subjects: 130
Study 8666176 — intervention group
Group type: COMPARATOR
Intervention: Maximal bicycle exercise electrocardiography (TE)
Number of subjects: 130
Study 8666176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TED and TE results
Number of subjects: 130
Study 8666176 — intervention group
Group type: EXPERIMENTAL
Intervention: TED
Number of subjects: 130
Study 1632167 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.003 and 0.0075 mg/kg)
Number of subjects: 100
Study 1632167 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.006 and 0.015 mg/kg)
Number of subjects: 100
Study 1632167 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 100
Study 1632167 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 100
Study 6544449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (social medical intervention by nurses experienced in geriatrics)
Number of subjects: 4128
Study 6544449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 4128
Study 6544449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 4128
Study 6544449 — intervention group
Group type: COMPARATOR
Intervention: Intervention group and Control group
Number of subjects: 4128
Study 3554881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid 1% eye drops
Number of subjects: 250
Study 3554881 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 0.5% eye drops
Number of subjects: 250
Study 30971282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless single-port video-assisted thoracic surgery (Tubeless‐SPVATS) via anterior mediastinum
Number of subjects: 18
Study 28986425 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Consent
Number of subjects: 47
Study 28986425 — intervention group
Group type: COMPARATOR
Intervention: Conventional consent
Number of subjects: 47
Study 25980345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive raloxifene treatment (120 mg per day)
Number of subjects: 98
Study 25980345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 23731173 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise group
Number of subjects: 60
Study 23731173 — intervention group
Group type: COMPARATOR
Intervention: Education group
Number of subjects: 60
Study 23731173 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise group
Number of subjects: 60
Study 22289524 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil/leucovorin (NCT group)
Number of subjects: 55
Study 22289524 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy alone (non-NCT group)
Number of subjects: 55
Study 18065570 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based physical activity intervention
Number of subjects: 0
Study 18065570 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16400334 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (n = 74 patients, group I)
Number of subjects: 219
Study 16400334 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (n = 87 patients, group II)
Number of subjects: 219
Study 15228463 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide IV
Number of subjects: 58
Study 15228463 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/kg metoclopramide IV (up to 32 mg)
Number of subjects: 58
Study 11390121 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodiol 300 microg, once daily
Number of subjects: 408
Study 11390121 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol 2 mg/day
Number of subjects: 408
Study 9245039 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I
Number of subjects: 337
Study 9245039 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP‐3
Number of subjects: 337
Study 8426213 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA ploidy analysis
Number of subjects: 502
Study 8426213 — intervention group
Group type: EXPERIMENTAL
Intervention: %S greater than 12.3 as a prognostic variable
Number of subjects: 502
Study 8426213 — intervention group
Group type: EXPERIMENTAL
Intervention: %S adjusted for clinical characteristics
Number of subjects: 502
Study 2890156 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoactive agents
Number of subjects: 2
Study 2890156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31431385 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative whole breast irradiation (WBI) + Tumour bed boost (TBB) (16 Gy in 8 fractions)
Number of subjects: 1608
Study 31431385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated WBI (42.5 Gy in 16 fractions)
Number of subjects: 1608
Study 31431385 — intervention group
Group type: COMPARATOR
Intervention: Conventional WBI (50 Gy in 25 fractions)
Number of subjects: 1608
Study 30423197 — intervention group
Group type: EXPERIMENTAL
Intervention: Any HAC‐OP
Number of subjects: 434
Study 30423197 — intervention group
Group type: EXPERIMENTAL
Intervention: HAC‐OP
Number of subjects: 434
Study 27999851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Lecithin, 2400 mg daily)
Number of subjects: 24
Study 27999851 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (eicosapentaenoic acid (EPA); 1770 mg, and docosahexaenoic acid (DHA); 390 mg, daily)
Number of subjects: 24
Study 27999851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1,000 IU daily)
Number of subjects: 24
Study 27999851 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Placebo, Omega-3, Vitamin D)
Number of subjects: 24
Study 26210542 — intervention group
Group type: EXPERIMENTAL
Intervention: IPFA: 2 extra professionally-delivered fluoride applications per year
Number of subjects: 0
Study 26210542 — intervention group
Group type: EXPERIMENTAL
Intervention: NOCTP: non-operative caries treatment programme
Number of subjects: 0
Study 26210542 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 0
Study 22367681 — intervention group
Group type: EXPERIMENTAL
Intervention: Core‐FM symptoms
Number of subjects: 216
Study 22367681 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress
Number of subjects: 216
Study 22367681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined index of symptom severity (the CODI)
Number of subjects: 216
Study 20971128 — intervention group
Group type: EXPERIMENTAL
Intervention: EX(1)
Number of subjects: 12
Study 20971128 — intervention group
Group type: EXPERIMENTAL
Intervention: EX(2)
Number of subjects: 12
Study 20971128 — intervention group
Group type: COMPARATOR
Intervention: SED
Number of subjects: 12
Study 20971128 — intervention group
Group type: EXPERIMENTAL
Intervention: EX(1), EX(2), SED
Number of subjects: 12
Study 18429857 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried fascia
Number of subjects: 150
Study 18429857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh fascia
Number of subjects: 150
Study 18429857 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried and rehydrated fascia
Number of subjects: 150
Study 16942960 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental reinstatement of the treatment context before follow-up test
Number of subjects: 48
Study 16942960 — intervention group
Group type: COMPARATOR
Intervention: Exposure therapy in one of two contexts
Number of subjects: 48
Study 12940592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GK501) 120 mg
Number of subjects: 11
Study 12940592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11098268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin plus vancomycin
Number of subjects: 151
Study 11098268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin alone
Number of subjects: 151
Study 11098268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 9249121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (1.5 mg/kg) + Morphine (0.1 mg/kg)
Number of subjects: 12
Study 9249121 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 12
Study 9249121 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen (1.5 mg/kg)
Number of subjects: 12
Study 8322695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 9
Study 8322695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg orally)
Number of subjects: 9
Study 8322695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 mg sublingually)
Number of subjects: 9
Study 3011329 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10‐40 mg/day, p.o., for 6 weeks)
Number of subjects: 14
Study 3011329 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg/day, p.o.) alone for 2 weeks
Number of subjects: 14
Study 3011329 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg/day, p.o.) in combination with propranolol (80‐160 mg/day, p.o.) for 4 weeks
Number of subjects: 14
Study 30938299 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Tdap vaccination at 30–32 weeks of pregnancy
Number of subjects: 118
Study 30938299 — intervention group
Group type: COMPARATOR
Intervention: Control group (Tdap vaccination within 48 h after delivery)
Number of subjects: 118
Study 30938299 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Tdap vaccination
Number of subjects: 118
Study 30938299 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 29077468 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization of the pseudodipolar interaction in the spin-orbit-generated low-energy Hamiltonian
Number of subjects: 0
Study 29077468 — intervention group
Group type: COMPARATOR
Intervention: Absence of quenched disorder
Number of subjects: 0
Study 26587088 — intervention group
Group type: EXPERIMENTAL
Intervention: NPS EMS length‐based pediatric emergency resuscitation tape
Number of subjects: 20
Study 26587088 — intervention group
Group type: COMPARATOR
Intervention: Standard methods to determine medication dosing (control)
Number of subjects: 20
Study 22682471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmented sleep
Number of subjects: 12
Study 22682471 — intervention group
Group type: COMPARATOR
Intervention: Non-fragmented sleep
Number of subjects: 12
Study 20638190 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTOCLO (800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week)
Number of subjects: 54
Study 20638190 — intervention group
Group type: EXPERIMENTAL
Intervention: PENTOCLO
Number of subjects: 54
Study 19705519 — intervention group
Group type: EXPERIMENTAL
Intervention: Five sessions of individual and family counseling (+ prn ad hoc counseling)
Number of subjects: 155
Study 19705519 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 155
Study 16679904 — intervention group
Group type: EXPERIMENTAL
Intervention: NewYork‐Presbyterian Dexterity Glove (NYPDG)
Number of subjects: 18
Study 16679904 — intervention group
Group type: COMPARATOR
Intervention: Standard, custom‐made pressure glove
Number of subjects: 18
Study 15324522 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate 200 mg + ezetimibe 10 mg
Number of subjects: 32
Study 15324522 — intervention group
Group type: COMPARATOR
Intervention: fenofibrate 200 mg
Number of subjects: 32
Study 15324522 — intervention group
Group type: COMPARATOR
Intervention: ezetimibe 10 mg
Number of subjects: 32
Study 15324522 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 10926898 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine extract (1 g/day, equivalent to 375 mL of red wine)
Number of subjects: 21
Study 10926898 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (30 mg/day)
Number of subjects: 21
Study 10926898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10926898 — intervention group
Group type: COMPARATOR
Intervention: Washout
Number of subjects: 21
Study 9366937 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% end‐tidal desflurane increased to 6% and then 9% for 15‐min intervals in group 2 (intervention group).
Number of subjects: 15
Study 9366937 — intervention group
Group type: COMPARATOR
Intervention: 3% end‐tidal desflurane maintained for 60 min in group 1 (control group).
Number of subjects: 15
Study 8359587 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant insulin-like growth factor I (40 micrograms/kg body weight)
Number of subjects: 9
Study 3024866 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg orally)
Number of subjects: 8
Study 3024866 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose naloxone infusion (180 min after loperamide administration)
Number of subjects: 8
Study 30741866 — intervention group
Group type: EXPERIMENTAL
Intervention: No-device group (ND); no electronic devices could be used after dinner or overnight
Number of subjects: 49
Study 30741866 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON); unrestricted electronic device use
Number of subjects: 49
Study 30741866 — intervention group
Group type: EXPERIMENTAL
Intervention: No-device group (ND)
Number of subjects: 49
Study 30741866 — intervention group
Group type: EXPERIMENTAL
Intervention: Triathletes (ND)
Number of subjects: 49
Study 30741866 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 49
Study 30485922 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole soybeans
Number of subjects: 60
Study 30485922 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy powder
Number of subjects: 60
Study 30485922 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean milk
Number of subjects: 60
Study 30485922 — intervention group
Group type: COMPARATOR
Intervention: Bean curd cake
Number of subjects: 60
Study 30485922 — intervention group
Group type: COMPARATOR
Intervention: Dried bean curd stick
Number of subjects: 60
Study 30485922 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 60
Study 26912284 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional en masse repair
Number of subjects: 82
Study 26912284 — intervention group
Group type: COMPARATOR
Intervention: Separate double-layer double-row repair
Number of subjects: 82
Study 24937541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO; 15 mg for 6 weeks, then 30 mg daily)
Number of subjects: 42
Study 24937541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 42
Study 24937541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22431401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation and emotion skills training (CREST) plus treatment as usual
Number of subjects: 81
Study 22431401 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 81
Study 20668284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 225
Study 20668284 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 225
Study 20668284 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 225
Study 20668284 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CBT
Number of subjects: 225
Study 17699008 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 L1 protein viruslike particle AS04 candidate vaccine (n = 1088)
Number of subjects: 2189
Study 17699008 — intervention group
Group type: COMPARATOR
Intervention: Control hepatitis A vaccine (n = 1101)
Number of subjects: 2189
Study 16232176 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) induced labor (35 women)
Number of subjects: 70
Study 16232176 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous active labor (35 women)
Number of subjects: 70
Study 12196667 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (temporal lobectomy)
Number of subjects: 10
Study 9990561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (300 mg/day, increased to 600 and 900 mg/day if tolerated)
Number of subjects: 8
Study 9990561 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuroleptic (initial treatment for 6 weeks)
Number of subjects: 8
Study 7750340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bennett Cascade 2 vaporizing humidifier
Number of subjects: 9
Study 7750340 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR Hygroster HME
Number of subjects: 9
Study 7750340 — intervention group
Group type: COMPARATOR
Intervention: Pall Ultipor HME
Number of subjects: 9
Study 1520205 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid
Number of subjects: 50
Study 1520205 — intervention group
Group type: EXPERIMENTAL
Intervention: mefenamic acid
Number of subjects: 50
Study 1520205 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 6648051 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading
Number of subjects: 20
Study 6648051 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory resistive loading
Number of subjects: 20
Study 6648051 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 20
Study 30995952 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-week exercise program combined with case management
Number of subjects: 419
Study 30995952 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 419
Study 30020330 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture protocol (6 sessions, 24 minutes each, over 6 weeks)
Number of subjects: 102
Study 30020330 — intervention group
Group type: COMPARATOR
Intervention: Simulated laser-acupuncture sessions
Number of subjects: 102
Study 24423117 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥6-portion/day F&V diet
Number of subjects: 80
Study 24423117 — intervention group
Group type: COMPARATOR
Intervention: 1-portion/day F&V diet
Number of subjects: 80
Study 22955359 — intervention group
Group type: EXPERIMENTAL
Intervention: L. salivarius LS01 (probiotic)
Number of subjects: 38
Study 22955359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19405020 — intervention group
Group type: EXPERIMENTAL
Intervention: False-evidence ploys
Number of subjects: 0
Study 19405020 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert testimony
Number of subjects: 0
Study 19405020 — intervention group
Group type: EXPERIMENTAL
Intervention: Demeanor ploys
Number of subjects: 0
Study 17294204 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐assisted uvulopalatoplasty (LAUP)
Number of subjects: 44
Study 17294204 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency-assisted uvulopalatoplasty (RAUP)
Number of subjects: 44
Study 17294204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LAUP and RAUP
Number of subjects: 44
Study 15383111 — intervention group
Group type: EXPERIMENTAL
Intervention: Five or more caesarean sections
Number of subjects: 308
Study 15383111 — intervention group
Group type: COMPARATOR
Intervention: Third or fourth caesarean sections
Number of subjects: 308
Study 11438489 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degrees (Nissen) fundoplication
Number of subjects: 200
Study 11438489 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 degrees (Toupet) fundoplication
Number of subjects: 200
Study 11438489 — intervention group
Group type: COMPARATOR
Intervention: Preoperative esophageal dysmotility
Number of subjects: 200
Study 11438489 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative esophageal motility
Number of subjects: 200
Study 9597052 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 341
Study 9597052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 9597052 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (in hypertensive patients)
Number of subjects: 341
Study 9597052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in hypertensive patients)
Number of subjects: 341
Study 9597052 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (in normotensive patients)
Number of subjects: 341